{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:45:05Z","timestamp":1765961105934,"version":"3.37.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100007334","name":"Ministry of Health and Family Welfare","doi-asserted-by":"publisher","award":["NPHCE"],"award-info":[{"award-number":["NPHCE"]}],"id":[{"id":"10.13039\/501100007334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s10072-018-3662-1","type":"journal-article","created":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T15:28:01Z","timestamp":1543678081000},"page":"1077-1080","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["L-type calcium channel blockers and a symptom complex mimicking de Melo-Souza\u2019s syndrome"],"prefix":"10.1007","volume":"40","author":[{"given":"Upinder","family":"Kaur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pritam","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indrajeet Singh","family":"Gambhir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7737-0016","authenticated-orcid":false,"given":"Sankha Shubhra","family":"Chakrabarti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,1]]},"reference":[{"issue":"6","key":"3662_CR1","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1517\/14740338.2015.1032244","volume":"14","author":"D Z\u00e1dori","year":"2015","unstructured":"Z\u00e1dori D, Veres G, Szal\u00e1rdy L, Kliv\u00e9nyi P, V\u00e9csei L (2015) Drug-induced movement disorders. Expert Opin Drug Saf 14(6):877\u2013890","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"3662_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.9740\/mhc.n90206","volume":"1","author":"JJ Chen","year":"2012","unstructured":"Chen JJ (2012) Drug-induced movement disorders. Mental Health Clin 1(7):167\u2013173","journal-title":"Mental Health Clin"},{"issue":"3B","key":"3662_CR3","first-page":"957","volume":"67","author":"HA Teive","year":"2009","unstructured":"Teive HA, Munhoz RP, Ferraz HB (2009) Flunarizine and cinnarizine-induced Parkinsonism: 25 years of de Melo-Souza\u2019s syndrome. Arq Neuropsiquiatr 67(3B):957","journal-title":"Arq Neuropsiquiatr"},{"key":"3662_CR4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.parkreldis.2003.12.004","volume":"10","author":"HAG Teive","year":"2004","unstructured":"Teive HAG, Troiano AR, Germiniani FMB, Werneck LC (2004) Flunarizine and cinnarizine-induced Parkinsonism: a historical and clinical analysis. Parkinsonism Relat Disord 10:243\u2013245","journal-title":"Parkinsonism Relat Disord"},{"key":"3662_CR5","doi-asserted-by":"publisher","first-page":"iii22","DOI":"10.1136\/jnnp.2004.045906","volume":"75","author":"RJ Martin","year":"2004","unstructured":"Martin RJ (2004) Central pontine and extrapontine myelinolysis: the osmotic demyelination syndromes. J Neurol Neurosurg Psychiatry 75:iii22\u2013iii28","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3662_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1159\/000185303","volume":"51","author":"ML Pedro-Botet","year":"1989","unstructured":"Pedro-Botet ML, Bonal J, Caralps A (1989) Nifedipine and myoclonic disorders. Nephron 51:281","journal-title":"Nephron"},{"key":"3662_CR7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00702-013-1108-8","volume":"121","author":"D Dressler","year":"2014","unstructured":"Dressler D (2014) Tardive dystonic syndrome induced by the calcium-channel blocker amlodipine. J Neural Transm 121:367\u2013369","journal-title":"J Neural Transm"},{"key":"3662_CR8","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.amjmed.2008.10.036","volume":"122","author":"EL Wallace","year":"2009","unstructured":"Wallace EL, Lingle K, Pierce D, Satko S (2009) Amlodipine-induced myoclonus. Am J Med 122:e7","journal-title":"Am J Med"},{"key":"3662_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10072-016-2771-y","volume":"38","author":"RP Munhoz","year":"2017","unstructured":"Munhoz RP, Bertucci FD, Teive HAG (2017) Not all drug-induced Parkinsonism are the same: the effect of drug class on motor phenotype. Neurol Sci 38:319\u2013324","journal-title":"Neurol Sci"},{"key":"3662_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nrneurol.2009.196","volume":"6","author":"WF Abdo","year":"2010","unstructured":"Abdo WF, Van De Warrenburg BP, Burn DJ, Quinn NP, Bloem BR (2010) The clinical approach to movement disorders. Nat Rev Neurol 6:29\u201337","journal-title":"Nat Rev Neurol"},{"key":"3662_CR11","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1016\/S0024-3205(97)00881-3","volume":"61","author":"S Uchida","year":"1997","unstructured":"Uchida S, Yamada S, Nagai K, Deguchi Y, Kimura R (1997) Brain pharmacokinetics and in vivo receptor binding of 1, 4-dihydropyridine calcium channel antagonists. Life Sci 61:2083\u20132090","journal-title":"Life Sci"},{"key":"3662_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.neuron.2009.04.010","volume":"62","author":"DJ Surmeier","year":"2009","unstructured":"Surmeier DJ (2009) A lethal convergence of dopamine and calcium. Neuron 62:163\u2013164","journal-title":"Neuron"},{"key":"3662_CR13","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s40263-016-0393-9","volume":"30","author":"T Swart","year":"2016","unstructured":"Swart T, Hurley MJ (2016) Calcium channel antagonists as disease-modifying therapy for Parkinson\u2019s disease: therapeutic rationale and current status. CNS Drugs 30:1127\u20131135","journal-title":"CNS Drugs"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-018-3662-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-018-3662-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-018-3662-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T08:12:10Z","timestamp":1575274330000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-018-3662-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,1]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["3662"],"URL":"https:\/\/doi.org\/10.1007\/s10072-018-3662-1","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2018,12,1]]},"assertion":[{"value":"22 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Elderly Pharmacovigilance Programme has the institutional ethics committee approval no. Dean\/2015-16\/IEC\/411.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was taken from patient\u2019s legal guardian (son) for publication of case and videos.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}